The accumulation of amyloid-β may be associated with the cognitive symptoms associated with COVID-19 and suggests that NRP1 inhibitors or antiviral medications may serve as therapeutic tools to prevent these consequences. This evidence concerns the gene NRP1 and COVID-19.